This company listing is no longer active
Salud financiera de hoja de balance de Elliptic Laboratories
Salud financiera controles de criterios 6/6
Elliptic Laboratories has a total shareholder equity of NOK314.0M and total debt of NOK9.0M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are NOK335.9M and NOK21.9M respectively.
Información clave
2.9%
Ratio deuda-patrimonio
NOK 9.00m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | NOK 153.95m |
| Patrimonio | NOK 314.01m |
| Total pasivo | NOK 21.90m |
| Activos totales | NOK 335.91m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: ELABSO's short term assets (NOK204.0M) exceed its short term liabilities (NOK16.3M).
Pasivo a largo plazo: ELABSO's short term assets (NOK204.0M) exceed its long term liabilities (NOK5.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ELABSO has more cash than its total debt.
Reducción de la deuda: ELABSO's debt to equity ratio has reduced from 36.7% to 2.9% over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ELABSO has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: ELABSO has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 7.4% each year.